The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Guillain‐Barré and Miller Fisher syndromes occurring with tumor necrosis factor α antagonist therapy
Abstract
Objective: Diverse neurologic syndromes have been described in association with tumor necrosis factor α (TNFα) antagonist therapy for inflammatory arthritides and Crohn's disease. The objective of this study was to review the occurrence and clinical features of Guillain‐Barré syndrome and its variant, the Miller Fisher syndrome, during TNFα antagonist therapy. Methods: The postmarketing database of the US Food and Drug Administration (FDA) was searched, following our experience with a patient with rheumatoid arthritis in whom the Miller Fisher syndrome variant of the Guillain‐Barré syndrome developed while he was receiving infliximab therapy. Results: Our index patient had a neurologic illness defined initially by ataxia and dysarthria, which fluctuated in relation to each subsequent infliximab infusion and, after 6 months, culminated in areflexic flaccid quadriplegia. In addition, 15 patients in whom Guillain‐Barré syndrome developed following TNFα antagonist therapy were identified from the FDA database. Guillain‐Barré syndrome developed following infliximab therapy in 9 patients, following etanercept therapy in 5 patients, and following adalimumab therapy in 1 patient. Among the 13 patients for whom followup data were available, 1 patient experienced no resolution, 9 patients had partial resolution, and 3 patients had complete resolution of Guillain‐Barré syndrome following therapy. Conclusion: An association of Guillain‐Barré syndrome with TNFα antagonist therapy is supported by the worsening of neurologic symptoms that occurred in our index patient following each infusion of infliximab, and by the temporal association of this syndrome with TNFα antagonist therapy in 15 other patients. An acute or subacute demyelinating polyneuropathy should be considered a potential adverse effect of TNFα antagonist therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling
Cope, A. P., Liblau, R. S., Yang, X.-D., Congia, M., Laudanna, C., Schreiber, R. D., Probert, L., Kollias, G., & McDevitt, H. O. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.9.1573 · Cited by 287 · cited 1×
“The prolonged administration of TNF antagonists is thought to enhance autoimmune responses by potentiating T cell receptor signaling and decreasing apoptosis of autoreactive T cells (14).”
Background
Cited by
Drug Allergy: An Updated Practice Parameter
(2010) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2010.08.002 · Cited by 957
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Autoimmune diseases induced by biological agents
Ramos-Casals, M., Roberto-Perez-Alvarez, Diaz-Lagares, C., Cuadrado, M.-J., & Khamashta, M. A. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.10.003 · Cited by 323
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Metadata
- Authors
- Shin, I. J., Baer, A. N., Kwon, H. J., Papadopoulos, E. J., & Siegel, J. N.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2006-04-27
- Volume
- 54
- Issue
- 5
- Pages
- 1429-1434
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2026229008
- Cited by
- 195
- References
- 2
- FWCI
- 8.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.